The Wild Story Behind A Promising Experimental Cancer Drug Forbes In 1997, IDEC delivered rituximab, the first monoclonal antibody approved by the FDA for cancer treatment; it is also used for the treatment of rheumatoid arthritis. IDEC merged with Biogen in 2003. Miller ultimately left IDEC, and in 1991 teamed up ... |
